



PATENT  
Atty. Dkt. No. PH-7038

TECH CENTER 1600/2900

OCT 18 2002

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re appln. of: Wong	)	
	)	
U.S. Serial No.: 09/519,188	)	
	)	
Filed: 03/06/2000	)	Examiner: Kim, V.
	)	
For: Treatment of Thrombosis by	)	
Combined Use of a Factor Xa	)	
Inhibitor and Aspirin, Tissue	)	Art Unit: 1614
Plasminogen Activator (TPA)	)	
a GPIIb/IIIa Antagonist, Low	)	
Molecular Weight Heparin or	)	
Heparin	)	

Hon. Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

DECLARATION UNDER 37 CFR 1.131

1. This declaration is to establish completion of the invention in this application in the United States, at a date prior to October 29, 1998 which is the earliest effective date of the 102(a) reference (Cariou et al. CA 2199642) that was cited by the Examiner.
2. The person making this declaration is the inventor.
3. The inventor conceived of the invention prior to the earliest effective date of said reference cited by the Examiner and was diligent from prior to the effective date to a subsequent reduction to practice.
4. To establish the date of completion of the invention of this application, a photocopy of a notebook entry is submitted herewith as "EXHIBIT A" as evidence.

5. From this document it can be seen that the invention in this application was made prior to the earliest effective date of the references cited by the Examiner.
6. The inventor was diligent from the time of conception of the invention till the invention was actually reduced to practice and through the date the application was filed with the U.S. Patent Office.
7. This declaration is being submitted prior to final rejection.
8. As a person signing below I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole inventor: Pancras C. Wong

Inventor's signature: 

Date: October 8, 2002

Country of Citizenship: United States

Residence: 3227 Whiteman Road, Wilmington, DE 19808

Post Office Address: 3227 Whiteman Road, Wilmington, DE 19808

OIP E  
OCT 15 2002  
PATENT & TRADEMARK OFFICE

RECEIVED

OCT 18 2002

SL

1590 43

EXHIBIT A

CONT. FROM p.  
DIRECTED BY

TECH CENTER 1600/2900

DATE  
SUBJECT

Claim

REFERENCE

Claim  
OBJECT

two different with different sites of  
anticoagulants and ~~as~~ ~~anticoagulant~~ for  
oxygenation would be synergistic in preventing  
thrombus formation for the treatment of  
thrombosis

Coadministration of an anticoagulant and an  
antiplatelet agent would be ~~also~~ synergistic in  
preventing thrombus formation for the treatment  
of thrombosis.

Proposed studies (possible synergistic,  
anti-thrombotic activity of  
① To examine a coadministration of a fxa inhibitor such as  
SF 303 and a <sup>direct</sup> thrombin inhibitor such as XU817  
at their subthreshold doses. Heparin ~~is~~ will also be  
examined

② To examine possible synergistic, anti-thrombotic  
activity of fxa inhibitor such as SF 303 and  
an antiplatelet agent such as ~~GP IIb/IIIa~~ inhibitor or  
thrombin-thrombosane A<sub>2</sub> receptor inhibitor or thromboxane  
synthase inhibitor or a cyclooxygenase dependent  
platelet ~~inhibitor~~ inhibitor such as aspirin or PGI<sub>2</sub>  
analogs.  
(Iloprost) & coumarin derivatives

③ To check <sup>coadministration</sup> GP IIb/IIIa inhibitor and fxa inhibitor in  
a guinea pig thrombosis model.

④ Another claim - fxa <sup>inhibitor</sup> such as SF 303 and  
direct thrombin inhibitor such as XU 817 ~~is~~ would be  
useful as adjuncts to thrombolytic therapy with tPA  
Claim ~~that~~ a fxa inhibitor or a direct thrombin ~~inhibitor~~ inhibitor  
together with tPA to induce thrombolysis ~~now~~ would  
lower the dose of tPA needed to induce thrombolysis.

EXPERIMENTER

WITNESS

Pamela Wong  
Alvina M Zaspel

DATE

DATE